目录号 | 产品详情 | 靶点 | |
---|---|---|---|
T10822 | Adenosine Receptor | ||
Cirsimarin (Cirsitakaoside) 是一种从 Microtea debilis 中分离出来的黄酮类化合物。它具有很强的抗脂肪生成作用,能减少小鼠脂肪组织的沉积。Cirsimarin 对腺苷 A1 受体有拮抗作用,对磷酸二酯酶有抑制作用 | |||
T8158 | Others | ||
Tilianin 是一种广泛存在于多种药用植物中的活性黄酮类苷,具有降压、保护心肌、降血脂、抗糖尿病、抗炎、抗氧化等作用。 | |||
TN3050 | Others | ||
4'-Methoxyflavanone 是一种从天然 Isaria fumosorosea KCH J2中分离得到的黄酮类化合物,可用于研究代谢疾病和心血管疾病。 | |||
T2933 | Apoptosis Wnt/beta-catenin CDK Autophagy | ||
Wogonin (Vogonin) 是一种具有细胞渗透性的口服类黄酮,具有抗炎和抗癌特性,能够抑制 CDK8和 Wnt 的活性。 | |||
T2778 | Antioxidant COX | ||
(+)-Catechin hydrate 是来自茶树的抗氧化类黄酮,可抑制环加氧酶-1,IC50为 1.4 μM。它是一种自由基清除剂,可防止多种生物系统中自由基介导的损害。 | |||
T0579 | Apoptosis PI3K Endogenous Metabolite Autophagy | ||
Myricetin (Cannabiscetin) 是一种存在于常见植物中的类黄酮,具有强抗氧化,抗糖尿病,抗癌和抗炎活性。 | |||
T3881 | Integrin Akt PERK AMPK | ||
Vaccarin 是从王不留行中提取的一种黄酮糖苷,可显著促进伤口愈合以及伤口部位的内皮和成纤维细胞增殖。它通过激活 AMPK 信号通路改善胰岛素抵抗和脂肪变性。 | |||
T2O2744 | Aromatase | ||
alpha-Naphthoflavone (7,8-benzoflavone) 是合成的黄酮类化合物,是一种竞争性芳香酶抑制剂,其IC50=0.5 μM,Ki=0.2 μM。 | |||
TN1819 | GSK-3 MEK PI3K | ||
Kaempferol 3-neohesperidoside (Kaempferol 3-O-neohesperidoside) 是一种类黄酮,对大鼠比目鱼肌具有拟胰岛素作用。 | |||
T2757 | PKC | ||
Myricitrin (Myricitrine) 是从杨梅根皮中分离出来的类黄酮化合物,具有镇痛作用。它是主要的抗氧化剂。 |
目录号 | 产品名/同用名 | 种属 | 表达系统 | ||
---|---|---|---|---|---|
TMPY-01579 | GBA3 Protein, Human, Recombinant (His) | Human | Baculovirus-Insect Cells | ||
Cytosolic beta-glucosidase, also known as Cytosolic beta-glucosidase-like protein 1, GBA3, CBG and CBGL1 is a cytoplasm protein which belongs to theglycosyl hydrolase 1 family and Klotho subfamily. GBA3 / CBGL1 is a glycosidase probably involved in the intestinal absorption and metabolism of dietary flavonoid glycosides. GBA3 / CBGL1 is present in small intestine (at protein level). GBA3 / CBGL1 is expressed in liver, small intestine, colon, spleen and kidney. GBA3 / CBGL1 is down-regulated in renal cell carcinomas and hepatocellular carcinomas. GBA3 / CBGL1 is able to hydrolyze a broad variety of glycosides including phytoestrogens, flavonols, flavones, flavanones and cyanogens. GBA3 / CBGL1 possesses beta-glycosylceramidase activity and may be involved in a nonlysosomal catabolic pathway of glycosylceramide.
|
|||||
TMPY-02041 | Cortisol Binding Globulin Protein, Human, Recombinant (His) | Human | HEK293 | ||
Corticosteroid-binding globulin (CBG), also known as SerpinA6, is a non-inhibitory member of the serine proteinase inhibitor (serpin) superfamily. It is the high-affinity transport protein for glucocorticoids in vertebrate blood. CBG is specifically cleaved by this protease at a precise site close to its carboxy-terminus. This induces a conformation change and disrupts the binding between glucocorticoids and CBG, and promotes a significant and local release of glucocorticoids (over 90% of them are bound to CBG in human plasma). In this context, CBG directs glucocorticoids to sites of inflammation, and plays in consequence a crucial role in efficient glucocorticoid action in physiology. The SerpinA6 protein is mainly secreted by the liver. This negative acute phase protein regulates free cortisol levels in the blood and distributes cortisol to its target tissues. SerpinA6 deficiency is an extremely rare hereditary disorder characterized by reduced corticosteroid-binding capacity with normal or low plasma corticosteroid-binding globulin concentration, and normal or low basal cortisol levels associated with hypo-/hypertension and muscle fatigue. There are three heritable, human CBG gene mutations that can reduce CBG-cortisol binding affinity and/or reduce circulating CBG levels.
|
|||||
TMPY-06702 | Cortisol Binding Globulin Protein, Mouse, Recombinant (His & Avi), Biotinylated | Mouse | HEK293 | ||
Corticosteroid-binding globulin (CBG), also known as SerpinA6, is a non-inhibitory member of the serine proteinase inhibitor (serpin) superfamily. It is the high-affinity transport protein for glucocorticoids in vertebrate blood. CBG is specifically cleaved by this protease at a precise site close to its carboxy-terminus. This induces a conformation change and disrupts the binding between glucocorticoids and CBG, and promotes a significant and local release of glucocorticoids (over 90% of them are bound to CBG in human plasma). In this context, CBG directs glucocorticoids to sites of inflammation, and plays in consequence a crucial role in efficient glucocorticoid action in physiology. The SerpinA6 protein is mainly secreted by the liver. This negative acute phase protein regulates free cortisol levels in the blood and distributes cortisol to its target tissues. SerpinA6 deficiency is an extremely rare hereditary disorder characterized by reduced corticosteroid-binding capacity with normal or low plasma corticosteroid-binding globulin concentration, and normal or low basal cortisol levels associated with hypo-/hypertension and muscle fatigue. There are three heritable, human CBG gene mutations that can reduce CBG-cortisol binding affinity and/or reduce circulating CBG levels.
|
|||||
TMPY-05099 | GBA/glucocerebrosidase Protein, Human, Recombinant (His) | Human | HEK293 | ||
Mutations in the GBA gene, encoding the lysosomal hydrolase glucocerebrosidase (GCase), are the most common known genetic risk factor for Parkinson's disease (PD) and dementia with Lewy bodies (DLB). ASAH1 (acid ceramidase 1) and GBA2 (glucocerebrosidase 2) enzymes that mediate glucosylsphingosine production and metabolism are attractive therapeutic targets for treating mutant GBA-associated PD.
|
|||||
TMPY-02107 | Cortisol Binding Globulin Protein, Mouse, Recombinant (His) | Mouse | HEK293 | ||
Corticosteroid-binding globulin (CBG), also known as SerpinA6, is a non-inhibitory member of the serine proteinase inhibitor (serpin) superfamily. It is the high-affinity transport protein for glucocorticoids in vertebrate blood. CBG is specifically cleaved by this protease at a precise site close to its carboxy-terminus. This induces a conformation change and disrupts the binding between glucocorticoids and CBG, and promotes a significant and local release of glucocorticoids (over 90% of them are bound to CBG in human plasma). In this context, CBG directs glucocorticoids to sites of inflammation, and plays in consequence a crucial role in efficient glucocorticoid action in physiology. The SerpinA6 protein is mainly secreted by the liver. This negative acute phase protein regulates free cortisol levels in the blood and distributes cortisol to its target tissues. SerpinA6 deficiency is an extremely rare hereditary disorder characterized by reduced corticosteroid-binding capacity with normal or low plasma corticosteroid-binding globulin concentration, and normal or low basal cortisol levels associated with hypo-/hypertension and muscle fatigue. There are three heritable, human CBG gene mutations that can reduce CBG-cortisol binding affinity and/or reduce circulating CBG levels.
|
|||||
TMPY-05329 | Cortisol Binding Globulin Protein, Human, Recombinant (His & Avi), Biotinylated | Human | HEK293 | ||
Corticosteroid-binding globulin (CBG), also known as SerpinA6, is a non-inhibitory member of the serine proteinase inhibitor (serpin) superfamily. It is the high-affinity transport protein for glucocorticoids in vertebrate blood. CBG is specifically cleaved by this protease at a precise site close to its carboxy-terminus. This induces a conformation change and disrupts the binding between glucocorticoids and CBG, and promotes a significant and local release of glucocorticoids (over 90% of them are bound to CBG in human plasma). In this context, CBG directs glucocorticoids to sites of inflammation, and plays in consequence a crucial role in efficient glucocorticoid action in physiology. The SerpinA6 protein is mainly secreted by the liver. This negative acute phase protein regulates free cortisol levels in the blood and distributes cortisol to its target tissues. SerpinA6 deficiency is an extremely rare hereditary disorder characterized by reduced corticosteroid-binding capacity with normal or low plasma corticosteroid-binding globulin concentration, and normal or low basal cortisol levels associated with hypo-/hypertension and muscle fatigue. There are three heritable, human CBG gene mutations that can reduce CBG-cortisol binding affinity and/or reduce circulating CBG levels.
|
|||||
TMPY-00027 | GSTT2B Protein, Human, Recombinant (His) | Human | HEK293 | ||
GSTT2B Protein, Human, Recombinant (His) is expressed in HEK293 with His tag. The predicted molecular weight is 29 kDa. Accession number: P0CG29
|